Close menu

$600,000 intended for funding the completion of preclinical research on Lys Therapeutics’ first-in-class monoclonal antibody, paving the way for a clinical trial in Parkinson’s disease


Lyon & Caen, France, 15 March 2023 – Lys Therapeutics, a French biotechnology company pioneering a revolutionary approach to treat patients suffering from neurodegenerative or neurovascular disorders, announced today that it has received more than $600,000 in funding from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) Translational Pipeline Program. This funding from a prestigious U.S. patient organization dedicated to the fight against Parkinson’s disease is further confirmation of the excellence of the research efforts around the mechanism of action of the antibody developed by Lys Therapeutics, Glunozumab.



Read the press release

More information